Feedback

Adjuvant therapy with Jianpi Huayu decoction improves overall and recurrence-free survival after hepatectomy for hepatocellular carcinoma: a retrospective propensity score-matching study

Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Luo, Rui;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Fang, Chongkai;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Chen, Chuyao;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Zhang, Ying;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Yao, Ruiwei;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Wang, Jinan;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Shi, Hanqian;
Affiliation
Department of Surgery, Baiyun Hospital of the First Affiliated Hospital of Guangzhou University of Chinese Medicine ,Guangzhou ,China
Feng, Kunliang;
Affiliation
The Second Affiliated Hospital of Guizhou University of Chinese Medicine ,Guizhou ,China
Hu, Mingli;
Affiliation
The First Clinical Medical School, Guangzhou University of Chinese Medicine ,Guangzhou ,China
Zhong, Chong

Hepatocellular carcinoma (HCC) patients experience high rates of recurrence following hepatectomy. Many herbal preparations used in traditional Chinese medicine have been shown to improve the postoperative condition of cancer patients. This retrospective study examined the efficacy and safety of Jianpi Huayu decoction (JPHYD) as adjuvant therapy for HCC following hepatectomy. HCC patients received postoperative management according to Chinese Society of Clinical Oncology recommendations, either alone (Control group) or in addition to daily JPHYD (1 week in hospital and 3 months after release). To reduce selection bias, we performed 1:1 propensity score matching between the Control and JPHYD groups. The main endpoint was recurrence-free survival (RFS), and secondary endpoints included overall survival (OS) and adverse event frequency. A total of 207 patients meeting inclusion criteria were enrolled, 127 in the Control group and 80 in the JPHYD group. Patients were then propensity score-matched, yielding each group of 80. Recurrence-free survival rate was significantly higher in the JPHYD group than in the Control group at 1 year (67.9% vs. 38.1%), 2 years (39.1% vs. 26.2%), and 3 years (31.3% vs. 26.2%) following hepatectomy (HR 0.5666 [95%CI, 0.3655 to 0.8784]; p = 0.0066). Additionally, OS was significantly higher in the JPHYD group than the Control group at 1 year (94.3% vs. 81.9%), 2 years (76.4% vs. 58.8%), and 3 years (66.3% vs. 51.4%) following hepatectomy (HR 0.5199 [95%CI, 0.2849 to 0.9490]; p = 0.027). Adverse events frequencies did not differ between the two groups. In conclusion, JPHYD can safely improve RFS and OS following hepatectomy for HCC.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: Copyright © 2023 Luo, Fang, Chen, Zhang, Yao, Wang, Shi, Feng, Hu and Zhong.

Use and reproduction: